IN2014KN00996A - - Google Patents

Info

Publication number
IN2014KN00996A
IN2014KN00996A IN996KON2014A IN2014KN00996A IN 2014KN00996 A IN2014KN00996 A IN 2014KN00996A IN 996KON2014 A IN996KON2014 A IN 996KON2014A IN 2014KN00996 A IN2014KN00996 A IN 2014KN00996A
Authority
IN
India
Prior art keywords
dexmedetomidine
administering
methods
subject matter
disclosed subject
Prior art date
Application number
Inventor
De Rocha Marcelo Garcia
Wayne Wisemandle
Dennis J Stalker
Edward Koo
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN00996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of IN2014KN00996A publication Critical patent/IN2014KN00996A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Abstract

The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery.
IN996KON2014 2011-10-14 2012-09-27 IN2014KN00996A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161547626P 2011-10-14 2011-10-14
US13/343,693 US20130096170A1 (en) 2011-10-14 2012-01-04 Methods of treating pediatric patients using dexmedetomidine
US13/471,403 US8324260B1 (en) 2011-10-14 2012-05-14 Methods of treating pediatric patients using dexmedetomidine
PCT/US2012/057652 WO2013055528A1 (en) 2011-10-14 2012-09-27 Methods of treating pediatric patients using dexmedetomidine

Publications (1)

Publication Number Publication Date
IN2014KN00996A true IN2014KN00996A (en) 2015-09-04

Family

ID=47226666

Family Applications (1)

Application Number Title Priority Date Filing Date
IN996KON2014 IN2014KN00996A (en) 2011-10-14 2012-09-27

Country Status (23)

Country Link
US (8) US20130096170A1 (en)
EP (2) EP3446691A1 (en)
JP (5) JP6270727B2 (en)
KR (3) KR20190029775A (en)
CN (2) CN103957906A (en)
AU (3) AU2012321246C1 (en)
BR (1) BR112014008983A2 (en)
CA (2) CA2978258A1 (en)
CY (1) CY1121041T1 (en)
DK (1) DK2766014T3 (en)
ES (1) ES2685814T3 (en)
HK (1) HK1200333A1 (en)
HR (1) HRP20181378T1 (en)
HU (1) HUE039671T2 (en)
IL (2) IL232070A0 (en)
IN (1) IN2014KN00996A (en)
LT (1) LT2766014T (en)
MX (1) MX362626B (en)
PL (1) PL2766014T3 (en)
PT (1) PT2766014T (en)
RS (1) RS57660B1 (en)
SI (1) SI2766014T1 (en)
WO (1) WO2013055528A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
EP3054931B1 (en) * 2013-10-07 2020-12-23 Teikoku Pharma USA, Inc. Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions
CN106456561B (en) 2013-10-07 2020-02-28 帝国制药美国公司 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety disorders, and insomnia using dexmedetomidine transdermal compositions
JP6188933B2 (en) 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド Methods and compositions for transdermal delivery of non-sedating amounts of dexmedetomidine
US11017330B2 (en) * 2014-05-20 2021-05-25 Elasticsearch B.V. Method and system for analysing data
CN106572820B (en) * 2014-08-18 2020-09-15 Epat有限公司 Pain assessment system
CN104784174A (en) * 2015-03-06 2015-07-22 北京大学第一医院 New pharmaceutical use of dexmedetomidine
US9717796B1 (en) * 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
JP2019534288A (en) * 2016-10-31 2019-11-28 テイコク ファーマ ユーエスエー インコーポレーテッド Method of pain management using dexmedetomidine transdermal delivery device
CN106539778A (en) * 2016-12-08 2017-03-29 武汉大学 Preoperative buccal oral cavity effervescent tablet of a kind of pediatric anesthesia and preparation method thereof
KR20240031326A (en) 2016-12-31 2024-03-07 바이오엑셀 테라퓨틱스 인코포레이티드 Use of Sublingual Dexmedetomidine for the treatment of Agitation
US11621969B2 (en) 2017-04-26 2023-04-04 Elasticsearch B.V. Clustering and outlier detection in anomaly and causation detection for computing environments
US11783046B2 (en) 2017-04-26 2023-10-10 Elasticsearch B.V. Anomaly and causation detection in computing environments
CN108042533B (en) * 2017-12-25 2020-11-13 苏州格兰科医药科技有限公司 Use of dexmedetomidine in the preparation of a pharmaceutical composition for preventing and/or inhibiting neuronal death following traumatic brain injury
US20210267944A1 (en) * 2018-06-27 2021-09-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CA3103431A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
AU2019339352A1 (en) * 2018-09-12 2021-03-25 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
EP3849532A4 (en) * 2018-09-13 2022-06-08 Taiwan Liposome Company, Ltd. Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
CA3123033A1 (en) * 2018-12-13 2020-06-18 Dignity Health System and method for detection and monitoring of over sedation to prevent harm to patients
US10817669B2 (en) 2019-01-14 2020-10-27 International Business Machines Corporation Automatic classification of adverse event text fragments
CN109793709A (en) * 2019-02-22 2019-05-24 青岛农业大学 A kind of harbor seal compound injection and preparation method thereof
US11000488B2 (en) * 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US20230165520A1 (en) * 2020-04-17 2023-06-01 Bioventures, Llc Methods and systems for predicting the effect of inhaled and infused anesthetics
KR20230094816A (en) 2021-12-21 2023-06-28 충남대학교산학협력단 Method for determining the dose of vancomycin in infectious disease patents
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
JPS6058890A (en) 1983-09-13 1985-04-05 Mizusawa Ind Chem Ltd Filler for thermal recording paper
FI844786A0 (en) 1984-12-04 1984-12-04 Farmos Oy TERAPEUTISKT UTNYTTJBAR FOERENING.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (en) 1989-10-17 1989-10-17 Farmos Oy EN TERAPEUTISKT VAERDEFULL FOERENING.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
EP0585368B1 (en) 1991-04-25 1997-08-06 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DE69332105T2 (en) 1992-09-29 2003-03-06 Inhale Therapeutic Systems San PULMONAL DELIVERY OF ACTIVE FRAGMENT OF PARATHORMON
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
FR2718357B1 (en) 1994-04-06 1997-10-03 Defarges Alain Moreau Improvements made to a needleless jet injection device.
DE69519300T2 (en) 1994-08-08 2001-05-31 Debiopharm Sa STABLE MEDICINAL PRODUCT CONTAINING OXALIPLATINE
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19749724A1 (en) 1997-11-11 1999-06-10 Gruenenthal Gmbh Use of a combination of opioid and alpha-adrenergic agonist in pain relievers
US6716867B1 (en) * 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (en) * 1998-04-01 2001-05-16 Orion Corp USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
PE20001396A1 (en) 1999-01-18 2000-12-23 Gruenenthal Chemie DELAYED MEDICINAL FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID OR A PHYSIOLOGICALLY TOLERABLE SALT OF THE SAME, AN O-AGONIST
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6806291B1 (en) 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
US20080308444A1 (en) 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US7896843B2 (en) * 2008-10-15 2011-03-01 Bioquiddity, Inc. Special purpose fluid dispenser
US8100890B2 (en) * 2008-10-15 2012-01-24 Bioquiddity, Inc. Special purpose fluid dispenser with pre-filled reservoir
US8603497B2 (en) 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
EP2429521B1 (en) 2009-05-15 2017-10-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
US20110152271A1 (en) 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
FR2959414B1 (en) 2010-04-30 2016-01-08 Luc Quintin COMBINATION OF MOLECULES FOR THE TREATMENT OF HYPOTENSION DURING SEPTIC, CARDIOGENIC, OR ANAPHYLACTIC REFRACTORY OR TERMINAL HEMORRHAGIC SHOCK, AFTER CORRECTION OF VOLEMIE AND STATE OF REFRACTORY MAL ASTHMATIC
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Also Published As

Publication number Publication date
BR112014008983A2 (en) 2017-05-02
JP2018027971A (en) 2018-02-22
HK1200333A1 (en) 2015-08-07
AU2017206211A1 (en) 2017-08-03
US8324260B1 (en) 2012-12-04
US20210137891A1 (en) 2021-05-13
US20160067220A1 (en) 2016-03-10
PL2766014T3 (en) 2019-02-28
HUE039671T2 (en) 2019-01-28
RS57660B1 (en) 2018-11-30
CY1121041T1 (en) 2019-12-11
CN103957906A (en) 2014-07-30
US20190269657A1 (en) 2019-09-05
US8507542B2 (en) 2013-08-13
JP2022008828A (en) 2022-01-14
JP6640164B2 (en) 2020-02-05
EP2766014B1 (en) 2018-07-18
KR20200019791A (en) 2020-02-24
IL249991A0 (en) 2017-03-30
EP2766014A1 (en) 2014-08-20
MX2014004548A (en) 2015-02-12
HRP20181378T1 (en) 2018-10-19
DK2766014T3 (en) 2018-09-24
AU2019203564A1 (en) 2019-06-13
AU2012321246A1 (en) 2014-05-01
AU2017206211B2 (en) 2019-02-28
CA2851780A1 (en) 2013-04-18
ES2685814T3 (en) 2018-10-11
KR20190029775A (en) 2019-03-20
LT2766014T (en) 2018-08-27
US20130096172A1 (en) 2013-04-18
IL232070A0 (en) 2014-05-28
JP6270727B2 (en) 2018-01-31
CA2851780C (en) 2017-11-28
CA2978258A1 (en) 2013-04-18
CN109700806A (en) 2019-05-03
PT2766014T (en) 2018-10-11
US20130096171A1 (en) 2013-04-18
US9314449B2 (en) 2016-04-19
EP2766014A4 (en) 2015-06-24
JP2014528474A (en) 2014-10-27
AU2012321246B2 (en) 2017-05-04
US20140005243A1 (en) 2014-01-02
JP2023179764A (en) 2023-12-19
WO2013055528A1 (en) 2013-04-18
MX362626B (en) 2019-01-28
KR20140094539A (en) 2014-07-30
US20130096170A1 (en) 2013-04-18
EP3446691A1 (en) 2019-02-27
AU2012321246C1 (en) 2017-11-02
SI2766014T1 (en) 2018-11-30
JP2020073529A (en) 2020-05-14

Similar Documents

Publication Publication Date Title
IN2014KN00996A (en)
UA115139C2 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
NZ732507A (en) Improved compositions for treating muscular dystrophy
WO2012023623A3 (en) Agent for treatment of hunter syndrome
MY173215A (en) Acetylcysteine compositions and methods of use thereof
EP3904502A3 (en) Compositions and methods
GB2491328A (en) Immediate/delayed drug delivery
GB2491327A (en) Delayed prolonged drug delivery
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
MX2014002171A (en) Combination treatments for hepatitis c.
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
EP2726066A4 (en) Dosage forms for oral administration and methods of treatment using the same
NZ714963A (en) Compositions and methods for treating anemia
EP2702994A3 (en) Methods of administering pirfenidone therapy
GB201111485D0 (en) Drug composition and its use in therapy
CL2014002935A1 (en) Method to treat a human patient with multiple sclerosis with laquinimod, at a daily dose of about 1.2mg; an oral unit dosage form of 1.2 mg of laquinimod and a carrier
MX350666B (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia.
UA105191C2 (en) Treatment with pirfenidone of patients with abnormal liver function
IN2014CN00315A (en)
MX2013006319A (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer.
MX348418B (en) Ocular composition containing bromfenac with increased bioavailability.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
GB201022049D0 (en) Methods
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor